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cellular reactions such as DNA repair,
growth inhibition, inflammation, and, in
the case of melanocytes, to increased
melanin production. Liebel et al. (2012)
analyzed signal transduction pathways and
found that visible light activates the EGFR–
ERK pathway. This activation of EGFR–ERK
has been demonstrated for UV irradiation
(Huang et al., 1996), and might explain the
expression of MMPs in response to visible
light, and it points toward a role for visible
light in premature skin aging. Given the
fact that many different molecules in
human skin absorb photons in the visible
wavelength range, it is unlikely that only
the EGFR–ERK pathway is activated. Here,
again, more research is needed to under-
stand the biological effects of visible light.
Conclusion
There is increasing evidence that visible
light can damage human skin. This effect
might seem negligible compared with
that of UV-induced skin damage; how-
ever, with sunscreen products providing
effective protection in the full UV range,
the remaining visible light might become
a more relevant source of sun-induced
oxidative stress. Liebel et al. (2012)
showed that sunscreens with effective
antioxidants might be a suitable means
of reducing visible light–induced ROS
and premature skin aging. Future
research is required to establish the
clinical relevance of these studies.
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Clinical Implications
 Visible light, especially in the blue light range, significantly impacts human
skin physiology.
 Sunscreens are designed to protect against UVR, but they do not block
visible light–induced reactive oxygen species (ROS); therefore, the
addition of antioxidants would provide additional protection against
oxidative stress.
 The overall contributions of visible light to oxidative stress reactions in
human skin induced by sunlight must be determined.
Double Trouble: Homozygous
Dominant Mutations and Hair Loss
in Pachyonychia Congenita
Alan D. Irvine1
In this issue, Wilson et al. report the first case of homozygous dominant negative
mutations in KRT17 in pachyonychia congenita (PC). Homozygous dominant
negative mutations are a rare occurrence in keratin disorders and this is a first
report in PC. These mutations cause a distinct sub-phenotype of PC that is more
severe in the offspring of affected parents and has associated alopecia.
Journal of Investigative Dermatology (2012) 132, 1757–1759. doi:10.1038/jid.2012.121
The age of gene discovery for Mendelian
genodermatoses can be said to have
started in 1987 with the identification of
deletions in STS in recessive X-linked
ichthyosis (Bonifas et al., 1987); there
then followed more than a decade and
a half of sustained, highly productive dis-
covery, driven by several energetic groups
and enabled by refined mapping tech-
niques and the Human Genome Mapping
Project (Irvine and McLean, 2003). Scien-
tific insights were plentiful as the identi-
fication of causative genes in single-gene
disorders revealed previously unknown
or unsuspected molecular pathways and
mechanisms of disease, some of which
have significant implications for common
complex disorders (Chavanas et al., 2000).
Rare and unheralded genoderma-
toses, heretofore, like carefully curated
museum specimens, smothered under
the cumbrance of Ancient Greek and
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Latin verbiage in the less-visited recesses
of larger dermatological textbooks,
became fashionable to study once
again. The initial gene-identification
papers earned high-impact publications
and a large number of citations. Gene
identification had an energizing effect
on investigative dermatological research
in general, with many talented young
researchers being attracted by the
possibilities of genetic discovery.
This phase of discovery delivered
direct benefits to patients, including
clearer and more informative diagnos-
tics and better-informed genetic coun-
selling. In severe genodermatoses,
DNA-based prenatal diagnosis became
a clinical-service reality and, in selected
cases, pre-implantation genetic diagno-
sis was developed. Gene correction or
replacement therapy has, for many pre-
dictable and several less-predictable
reasons, taken longer than initially
envisioned and, like Yeats’ peace, con-
tinues to ‘come dropping slow’
(Yeats, 1892).
For some, the golden age of gene
identification had reached or nearly
reached completion in the early years
of the 21st century. The heft of recent
efforts in genetics and dermatology has,
understandably, focused on the themes
of complex disease and gene correction
therapy. For many there was a feeling
that in the field of gene identification all
the major conditions had been worked
out and that greater challenges, discov-
eries, and insights lay elsewhere. The
second-wave work that meticulously
made use of these new genetic data on
a broader scale and made these discov-
eries truly relevant to the clinician was
more time consuming, more expensive,
and less rewarded in academic metrics
and therefore, with exceptions such
as epidermolysis bullosa, less often
undertaken.
However, the satisfaction derived from
discovery, from making a new and
accurate genetic diagnosis, from a new
gene identification, or from the refine-
ment of genotype:phenotype correlation
continues. Researchers still extract
valuable information that has real clin-
ical relevance for affected families and
for clinicians in genodermatology prac-
tice. Progress is now being made in
two areas. Next-generation sequencing
techniques, in particular whole-exome
sequencing (WES), have enabled gene
identification in small families and even
in individual cases that would have
been too costly in consumables or in
human labor to analyze using pre-
viously available tools (Blaydon et al.,
2011). In addition, significant lessons
are being learned from analyses done
by large multinational collaborations of
clinicians and scientists involving many
hundreds of patients. It is evident that
rare or uncommon Mendelian geno-
dermatoses are not always best served
by the existing literature, vulnerable as it
is to selective ascertainment and report-
ing bias of unusual or noteworthy cases
and apparently novel or family-specific
conditions. Genodermatoses are further
open to misinterpretation due to poten-
tially misleading, but relatively common
phenomena such as incomplete pene-
trance and variable expression, as seen
in many Mendelian autosomal domi-
nant conditions. In some cases simple
misdiagnosis confuses the picture.
Furthermore, single-family reports have
often established as holy writ, disease
features that exist purely by chance in
selected individuals or families and that
have no genuine relationship to the
underlying genetic condition. Thus, the
picture an enquiring clinician might
draw from the literature of any given
case of genodermatosis often varies
significantly from the truth.
Clinical and genetic
correlations disclosed
autosomal double-
dominant mutations
in PC.
The best way to address and clarify
these complexities—to facilitate the sort-
ing out of what is common and uncom-
mon in any given condition, the wheat
that is worth keeping and the chaff that
should not be eaten, those features that
define a distinct subtype and those
that define genuinely distinct conditions—
is to assemble large-scale collaborative
efforts. The Pachyonychia Congenita
Project (PC Project; http://www.pachyo-
nychia.org/) is an exemplar of such an
approach. Founded in 2003, their model
of a highly motivated patient support
group working together with expert
clinicians and dedicated scientists has
contributed greatly to the development
of a clinical, genetic, and patient-
oriented picture of PC that has been
painted in both broader terms and in
finer detail than was previously possible.
The generation of patient registries, as is
now happening for epidermolysis bul-
losa and ichthyoses, is essential not only
for further understanding of disease fea-
tures but also for identification of appro-
priate patients for future clinical trials
and interventions.
With respect to nosology, old terms
such as PC-3, PC-4, and PC with alo-
pecia (van Steensel et al., 2001), now
recognized as Clouston syndrome (van
Steensel et al., 2003), can be avoided
and more accurate and informative desig-
nations such as PC-17 can be utilized.
The clinician who only rarely encounters
these disorders now has better guidance
and a more robust framework to make a
firm diagnosis. Furthermore, as an illustra-
tion of the effects of, and the necessity to
correct, reporting bias, previously misattri-
buted features such as deafness, mental
retardation, diabetes, bony abnormalities,
early menarche, and cataracts can be
safely excluded from the canon of PC
disease manifestations. Inaccurate associ-
ations add unnecessarily to the burden
that families with these conditions carry;
clarity around these issues does every-
one a service. Given the known genetic
heterogeneity in PC, accurate clinical
classification facilitates a more direc-
ted and efficient molecular diagnostic
approach.
Illustrating the substantial merit of this
type of consortium endeavor and the
requirement for careful second-phase
work after a disease gene is identified,
the PC Project continues to uncover new
phenotypic subtleties and genotype:phe-
notype correlations nearly 17 years after
the initial identification of the first cau-
sal genes in PC. A PC Project-supported
work earlier this year reported a new
clinical subtype of PC with transgre-
diens features (Harris et al., 2012). In
this issue, Wilson et al (2012) again
show the benefit of careful clinical and
genetic correlation by disclosing the first
autosomal double-dominant muta-
tions in PC. In this work, two families
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(one from the Middle East and another
of Hispanic origin) were identified
through the PC consortium. In each
family both parents had, or were anam-
nestically inferred to have, classical PC.
Their offspring had more severe than
normal PC and the additional feature
of scalp alopecia. The phenotypic simi-
larity between these two unrelated fami-
lies from different parts of the world
strongly suggests that this represents a
genuine disease subtype. This must be
a rare occurrence in keratin diseases
given that these conditions have been
well studied for 20 years and only a
small number of epidermolysis bullosa
simplex cases with double-dominant
mutations been reported. It is important
that clinicians practicing genodermatology
be aware of these cases; experience sug-
gests that first reports are often followed
by further recognition of similar cases.
The implications for genetic counselling
are important in that affected individuals
will have a 100% chance of transmitting
the condition.
This work reminds us that even
familiar and well-studied conditions
can yield further insight into a detailed
and thoughtful clinical and genetic
study.
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Type I IFNs at the Interface between
Cutaneous Immunity and Epidermal
Remodeling
Curdin Conrad1 and Michel Gilliet1
Type I IFNs are key cytokines in antiviral host defense. Preferentially expressed by
plasmacytoid dendritic cells, type I IFNs are induced by viral infection and in
common skin wounds. In this issue, Tohyama et al. identify a new link between
type I IFNs and epidermal remodeling, by showing that type I IFNs specifically
upregulate IL-22R expression on keratinocytes and, thereby, IL-22-mediated Stat3
phosphorylation in keratinocytes. The findings suggest that type I IFNs play dual
roles in human skin: first, they induce immune activation with the induction of
IL-22-producing T cells; second, they provide the interface between immune
activation and epidermal remodeling by increasing keratinocyte responsiveness
to IL-22.
Journal of Investigative Dermatology (2012) 132, 1759–1762. doi:10.1038/jid.2012.149
Type I IFNs are upstream triggers of
cutaneous immunity
Type I IFNs (including IFN-a and IFN-b)
are key cytokines in antiviral host
defense, owing to their ability to limit
viral replication and to promote immune
activation (Theofilopoulos et al., 2005;
Stetson and Medzhitov, 2006). Although
produced by all nucleated cells, type I
IFNs are preferentially expressed by a
rare type of circulating cells called plas-
macytoid dendritic cells (pDCs) (Siegal
et al., 1999). pDCs produce large
amounts of type I IFNs upon TLR7- and
TLR9-mediated recognition of viral RNA
and DNA delivered into endosomal
compartments by the invading virus
(Gilliet et al., 2008). Type I IFNs are
not expressed in healthy skin, but they
are rapidly induced in virally infected
skin in association with pDC infiltration
(Wollenberg et al., 2002; Vanbervliet
et al., 2003; Gerlini et al., 2006).
Type I IFNs are also induced in
common skin wounds (Gregorio et al.,
2010). Mechanical skin injury induces
rapid infiltration of pDCs and transient
activation of TLR7 and TLR9, leading
to their short-lived expression. These
cytokines were found to initiate local
inflammatory responses and accelerate
re-epithelialization of skin wounds
(Gregorio et al., 2010). By contrast, sus-
tained type I IFN production by pDCs
was found in psoriatic skin, early in
disease formation (Nestle et al., 2005).
Here, type I IFNs were found to trigger
the activation and expansion of auto-
immune T cells, leading to epidermal
hyperplasia and the development of
psoriatic plaques (Nestle et al., 2005).
In line with these findings, excessive
IFN-a signaling in the skin of IRF2-defi-
cient mice causes an inflammatory skin
disease resembling psoriasis (Hida et al.,
2000).
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